Ulcerative colitis medications

Ulcerative colitis medications encompass a range of pharmaceutical treatments designed to manage the chronic inflammation and ulceration of the colon and rectum characteristic of ulcerative colitis, a type of inflammatory bowel disease. These include aminosalicylates for mild cases, corticosteroids for acute flares, immunomodulators to suppress immune responses, biologics targeting specific inflammatory cytokines, and Janus kinase inhibitors that block intracellular signaling pathways involved in inflammation. They work by reducing mucosal inflammation, promoting tissue healing, achieving clinical remission, and preventing relapses through mechanisms such as cytokine inhibition, T-cell modulation, and interference with inflammatory cascades. General health applications focus primarily on controlling symptoms like bloody diarrhea, abdominal pain, and urgency in patients with moderate to severe disease, while minimizing complications such as toxic megacolon or colorectal cancer risk. Advanced therapies like anti-TNF agents, IL-23 inhibitors, and integrin antagonists offer options for those unresponsive to conventional treatments, aiming for endoscopic healing and sustained remission. These medications are tailored based on disease severity, location, and prior treatment failures, often combined in step-up or top-down approaches.